Front Page News
Annual Cure SMA Community Update Survey Ready for Your Input
Navigating the recent global health crisis, Coronavirus (COVID-19), has reinforced for us the importance of understanding what the SMA community is thinking, feeling, and experiencing. […]
Cure SMA Launches New COVID-19 Support Package
Despite the new reality of quarantines, remote working, and social distancing, Cure SMA would like you to know that our work for the SMA community […]
COVID-19 Assistance Program Available to SMA Community
Cure SMA realizes that quarantining is essential for individuals and families who live with SMA, many of whom are experiencing hardships due to the COVID-19 […]
Grant Announcement: Cure SMA Awards $190,000 Grant to Stephen Meriney, Ph.D., University of Pittsburgh
This article is the last in a series of Cure SMA grant announcements that have been shared throughout the past months. Cure SMA has awarded […]
Cure SMA Announces Cancellation of 2020 Annual SMA Conference and Research & Clinical Care Meeting
Cure SMA has been closely monitoring news and reports of the Coronavirus (COVID-19) outbreak, allowing us to make decisions about local events and offer new […]
Community Statement from AveXis Regarding Commitment to SMA Community Amid COVID-19 Pandemic
Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus […]
Community Statement from Genentech on Risdiplam Approval Timeline
Dear SMA Community, As part of our ongoing partnership and following your request to receive important information about the risdiplam clinical […]
Answering Your Coronavirus (COVID-19) Medical Questions
We want you to know that Cure SMA continues to be here for the entire SMA community. We remain vigilant in monitoring and responding to […]
Biogen Announces First Patient Treated With Higher Dose Of Spinraza In Phase 2/3 DEVOTE Study
Biogen today announced that the first patient has been treated in the global clinical study, DEVOTE. The study is designed to evaluate the safety, tolerability, […]
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing
AveXis, a Novartis company, announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant, and clinically meaningful therapeutic benefit in patients with spinal muscular […]